What is Formurex?
Formurex, Inc. operates as a specialized contract development and manufacturing organization (CDMO) serving the global pharmaceutical and biotechnology sectors. The company provides a comprehensive suite of services, including preformulation, formulation development, analytical testing, and stability studies. By bridging the gap between laboratory-scale research and clinical trial manufacturing, Formurex facilitates the transition of therapeutic candidates from bench to bedside. Their facility is uniquely equipped to handle controlled substances, providing a distinct competitive advantage in the development of complex drug delivery technologies. Having successfully supported approximately 35 distinct pharmaceutical and biotech entities, the firm has established a robust track record in navigating the complexities of early-phase clinical supply requirements.
How much funding has Formurex raised?
Formurex has raised a total of $127K across 1 funding round:
Debt
$127K
Debt (2021): $127K with participation from PPP
Key Investors in Formurex
PPP
Public-Private Partnership
What's next for Formurex?
The infusion of capital from the recent strategic investment is expected to accelerate Formurex's expansion into more complex formulation projects and enhance its analytical service offerings. As the company moves deeper into its lifecycle, the focus will likely shift toward increasing manufacturing capacity for phase I clinical supplies and deepening its regulatory compliance infrastructure. By leveraging its existing expertise in drug delivery, Formurex is well-positioned to capture additional market share as biotech firms increasingly outsource specialized development tasks to reliable, high-quality partners. Future growth will likely be driven by the continued demand for innovative formulation solutions that address the bioavailability and stability challenges inherent in modern drug pipelines.
See full Formurex company page
